SCHEMBL17588

SCHEMBL17588

CCOC(=O)[C@@H](N)Cc1cccnc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
SCN9A Q15858 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CASP1 P29466 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HPGD P15428 2/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
NLRP3 Q96P20 1/20 0.37
BRD4 O60885 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17587 1.00 SLC13A5 (0.43) SLC13A5L3MBTL1SMN1; SMN2KMT2AMEN1
SCHEMBL16907 0.79 CARM1 (0.41) SLC13A5KMT2AGAAHPGDLMNA
SCHEMBL16906 0.79 CARM1 (0.41) SLC13A5KMT2AGAAHPGDLMNA
SCHEMBL20543840 0.77 ALDH1A1 (0.47) SMN1; SMN2KMT2AMEN1SCN9AHPGD
SCHEMBL26985715 0.77 ALDH1A1 (0.47) SMN1; SMN2KMT2AMEN1SCN9AHPGD
SCHEMBL1124574 0.76 NLRP3 (0.49) SMN1; SMN2KMT2AMEN1GAASCN9A
SCHEMBL18175 0.76 SLC13A5 (0.42) SLC13A5L3MBTL1SMN1; SMN2KMT2AMEN1
SCHEMBL18176 0.76 SLC13A5 (0.42) SLC13A5L3MBTL1SMN1; SMN2KMT2AMEN1
SCHEMBL21117776 0.75 SCN9A (0.46) KMT2AMEN1GAASCN9AALDH1A1
SCHEMBL20543723 0.75 SCN9A (0.46) KMT2AMEN1GAASCN9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 SLC13A5 481/4885L3MBTL1 4623/4885SMN1; SMN2 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.